Page last updated: 2024-12-08

dexketoprofen trometamol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dexketoprofen trometamol: a water-soluble tromethamine salt of the racemic ketoprofen, rac(+-)-ketoprofen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID177976
SCHEMBL ID8759161
MeSH IDM0303241

Synonyms (19)

Synonym
dexketoprofen trometamol
(s)-ketoprofen trometamol
s-(+)-ketoprofen trometamol
156604-79-4
2-amino-2-(hydroxymethyl)propane-1,3-diol (s)-2-(3-benzoylphenyl)propanoate
SCHEMBL8759161
AKOS025402326
AC-8135
J-009320
A883562
2-amino-2-(hydroxymethyl)propane-1,3-diol;2-(3-benzoylphenyl)propanoic acid
2-(3-benzoylphenyl)propanoic acid--2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)
DTXSID60935485
BCP09921
dexcetoprofeno trometamol
2-amino-2-(hydroxymethyl)-1,3-propanediol(s)-3-benzoyl-alpha-methylbenzeneacetate
SB48327
dexketoprofen trometamo
dexketoprofene trometamolo

Research Excerpts

Overview

Dexketoprofen trometamol (DKT) is a water-soluble, nonselective NSAIDs. It is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations.

ExcerptReferenceRelevance
"Dexketoprofen trometamol (DKT) is a water-soluble, nonselective NSAIDs."( The deleterious effect of xylene-induced ear edema in rats: Protective role of dexketoprofen trometamol transdermal invasomes via inhibiting the oxidative stress/NF-κB/COX-2 pathway.
Abd El-Halim, SM; Ali, BM; El-Nabarawi, MA; Jasti, BR; Rashwan, KO; Soliman, SM; Teaima, MH, 2023
)
1.86
"Dexketoprofen trometamol is a modified non-selective COX inhibitor with a rapid onset of action that is available as both oral and parenteral formulations. "( A review of dexketoprofen trometamol in acute pain.
Hanna, M; Moon, JY, 2019
)
2.34
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug ketoprofen. "( [The effects of intravenous dexketoprofen on postoperative analgesia and morphine consumption in patients undergoing abdominal hysterectomy].
Erol, A; Keçecioğlu, M; Reisli, R; Tuncer, S, 2010
)
1.8
"Dexketoprofen trometamol is an effective and rapidly acting analgesic for the treatment of acute musculoskeletal injuries."( Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury.
Herington, J; Kapadia, Y; Leman, P, 2003
)
1.76
"Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of nonsteroidal anti-inflamatory drug ketoprofen. "( [Postoperatif ağrida deksketoprofen kullanimi].
Köstekçi, H; Otelcioğlu, S; Reisli, R; Tavlan, A; Tuncer, S, 2006
)
1.78

Actions

ExcerptReferenceRelevance
"Dexketoprofen trometamol may cause esophageal lesions."( Esophagitis due to dexketoprofen trometamol: a rare case report.
Aslan, M; Donmez, S; Karadas, S; Olmez, S; Yavuz, A, 2015
)
1.47

Toxicity

ExcerptReferenceRelevance
" Treatment- related adverse events were experienced by 16% of patients in the dexketoprofen trometamol group compared with 21."( Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: A multicentre, double-blind, randomised, parallel-group clinical trial.
Wagenitz, A; Zippel, H, 2006
)
0.8
" Adverse events (AEs) were recorded."( Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care.
Carne, X; Rios, J; Torres, F, 2009
)
0.59

Pharmacokinetics

ExcerptReferenceRelevance
" Dexketoprofen trometamol showed the most rapid absorption rate, with highest Cmax and shortest t(max) values, whereas dexketoprofen free acid had the slowest absorption rate, and ketoprofen had an intermediate absorption rate."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
1.53
" The main pharmacokinetic parameters were determined by a noncompartmental approach."( Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects.
Artigas, R; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J; Zapata, A, 2006
)
0.6
" Model-independent pharmacokinetic parameters were obtained."( Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function.
Artigas, R; Bertolotti, M; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J, 2006
)
0.59

Compound-Compound Interactions

ExcerptReferenceRelevance
" This may be particularly the case when triptan therapy is combined with a nonsteroidal anti-inflammatory drug (NSAID)."( Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; D'Onofrio, F; Frediani, F; Omboni, S; Pezzola, D; Reggiardo, G; Sette, G; Tullo, V; Valguarnera, F; Zava, D, 2014
)
0.4
" Therefore, the current study investigated the immune effects induced in healthy mice by repeated administration of tramadol alone or in combination with acetaminophen or dexketoprofen."( Immunomodulation by tramadol combined with acetaminophen or dexketoprofen: In vivo animal study.
Bryniarski, K; Cieślik, M; Fedor, A; Filipczak-Bryniarska, I; Gębicka, M; Kozlowski, M; Kruk, G; Nazimek, K; Nowak, B; Pełka-Zakielarz, J; Skalska, P, 2023
)
0.91

Bioavailability

This randomized three-way, crossover pharmacokinetic study was performed to determine whether food or an antacid alters the bioavailability of dexketoprofen trometamol.

ExcerptReferenceRelevance
"Recent reports have disagreed on whether the bioavailability of S(+)-ketoprofen is affected by the presence of R(-)-ketoprofen."( Bioavailability of S(+)-ketoprofen after oral administration of different mixtures of ketoprofen enantiomers to dogs.
Carganico, G; García, ML; López, S; Mauleón, D; Tost, D; Vilageliu, J, 1998
)
0.3
" In the first study, the relative bioavailability of a single oral capsule of dexketoprofen free acid 25 mg or dexketoprofen trometamol 25 mg (given as 37 mg of the trometamol salt) was compared to ketoprofen 50 mg in 18 healthy volunteers."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
0.84
"This randomized three-way, crossover pharmacokinetic study was performed to determine whether food or an antacid alters the bioavailability of dexketoprofen trometamol."( The effect of food and an antacid on the bioavailability of dexketoprofen trometamol.
Artigas, R; Barbanoj, MJ; Casini, A; De Luca, M; Gich, I; Mauleón, D; McEwen, J; Tost, D, 1998
)
0.74
" Its rapid absorption rate with higher maximum plasma concentrations and shorter time to maximum values suggest that this drug is a good option for acute migraine treatment."( Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study.
Maggioni, F; Mainardi, F; Pezzola, D; Zanchin, G; Zava, D, 2014
)
1.85

Dosage Studied

ExcerptRelevanceReference
" Groups of six rats received either vehicle or analgesic drug and antinociception was evaluated by evaluating the dose-response curves over time."( Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998
)
0.3
" Dexalgin was prescribed in dosage 75 mg daily during 5 days."( [Therapeutic effect of dexalgin on disturbances of vertebrogenic and nonvertebrogenic mechanisms in back pain].
Kryzhanovskiĭ, GN; Merkulov, IuA; Merkulova, DM, 2006
)
0.33
" Dose-response curves for DEX and TRM, individually and combined in a 1 : 1 proportion based on their potency were obtained, and the doses that produced a 50% inhibition calculated."( Antinociceptive and anti-exudative synergism between dexketoprofen and tramadol in a model of inflammatory pain in mice.
Miranda, HF; Puig, MM; Romero, MA, 2012
)
0.38
"Dexketoprofen has an antiepileptic feature and this effect increases as the dosage increases, however it is currently unknown through which mechanism this drug shows its anticonvulsant effect."( Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Aksoy, D; Erbaş, O; Solmaz, V, 2015
)
0.42
" SPF episodes at 24-h after early dosing were 25 % (Frova), 45 % (FroDex 25) and 41 % (FroDex 37."( Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group stu
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Colombo, B; Comi, G; Cortelli, P; Curone, M; D'Arrigo, G; d'Onofrio, F; Frediani, F; Omboni, S; Sette, G; Tullo, V; Valguarnera, F, 2015
)
0.42
" Because DT has a short half-life, high and frequent dosing is used in treatment."( Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay.
Kıyan, HT; Öztürk, AA, 2020
)
0.8
" Dose-response curves were carried out for dexketoprofen, tapentadol, and dexketoprofen-tapentadol combinations in the acetic acid-induced writhing test in mice."( Antinociception and less gastric injury with the dexketoprofen-tapentadol combination in mice.
Alonso-Castro, ÁJ; Franco de la-Torre, L; Granados-Soto, V; Isiordia-Espinoza, MA; Partida-Castellanos, EM; Rivas-Carrillo, JD; Vidaurrazaga-Lugo, J; Zapata-Morales, JR, 2021
)
0.62
"5, 2, 4, 8, 12, and 24 hours after tooth extraction were counted by numeric rating scale(NRS), and the total dosage of emergent analgesic drugs used in 24 hours was recorded."( [Oral dexketoprofen tromethamine for preemptive analgesia in extraction of impacted teeth: a randomized controlled double-blind trial].
Hao, XH; Liu, N; Wu, XB; Zhao, J; Zhou, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (179)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (5.03)18.2507
2000's35 (19.55)29.6817
2010's105 (58.66)24.3611
2020's30 (16.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 66.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index66.75 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index112.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (66.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials99 (52.11%)5.53%
Reviews10 (5.26%)6.00%
Case Studies16 (8.42%)4.05%
Observational1 (0.53%)0.25%
Other64 (33.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (54)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized-controlled Study; Comparison of the Effectiveness of Intravenous Ibuprofen and Intravenous Dexketoprofen in the Treatment of Migraine-related Headache in the Emergency Department [NCT04533568]Phase 4160 participants (Actual)Interventional2020-09-01Completed
Paracetamol Plus Morphine in ED [NCT03865004]Phase 4136 participants (Actual)Interventional2015-10-17Completed
Comparison of the Efficacy of Intravenous Dexketoprofen and Paracetamol in the Treatment of Pain in Patients Presenting to the Emergency Department With Sore Throat: A Double-Blinded, Randomized, Controlled Trial [NCT03768882]Phase 4200 participants (Actual)Interventional2017-12-01Completed
Effects of the Preoperative Administration of Dexketoprofen Trometamol on Pain and Swelling After Implant Surgery: a Randomized, Double-blind Controlled Trial. [NCT03107338]Phase 4100 participants (Actual)Interventional2013-09-30Completed
Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department [NCT02373514]Phase 4100 participants (Anticipated)Interventional2015-01-31Recruiting
Comparison of Dexketoprofen, Paracetamol and Ibuprofen in the Treatment of Primary Dysmenorrhea [NCT03697746]300 participants (Anticipated)Interventional2018-10-01Not yet recruiting
Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on the Patients That is Undergoing Abdominal Hysterectomy [NCT02092012]Phase 460 participants (Anticipated)Interventional2014-03-31Recruiting
Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam in Lumbar Disc Surgery [NCT02160236]Phase 490 participants (Anticipated)Interventional2014-11-30Recruiting
Impact of Preemptive Intravenous Ibuprofen on Intraoperative Analgesia in Third Molar Teeth [NCT03170726]60 participants (Anticipated)Interventional2017-05-15Active, not recruiting
[NCT02285972]Phase 4118 participants (Actual)Interventional2014-11-30Completed
Efficacy of Dexketoprofen Prescribed According to the Circadian Rhythms [NCT05176158]10 participants (Anticipated)Interventional2023-07-01Not yet recruiting
Analgesic Efficacy of Oral Dexketoprofen Trometamol/Tramadol Hydrochloride Versus Tramadol Hydrochloride/Paracetamol: a Randomised, Double-blind, Placebo and Active-controlled, Parallel Group Study in Moderate to Severe Acute Pain After Removal of Impacte [NCT02777970]Phase 4654 participants (Actual)Interventional2016-04-30Completed
Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Nontraumatic Musculoskeletal Pain in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial [NCT03122314]Phase 4200 participants (Actual)Interventional2015-08-31Completed
Comparison of Bioavailability of Dexketoprofen-Vit B vs Dexketoprofen (Stadium®), Dose 25 mg in Healthy Subjects, of Both Genders, Under Fasting Conditions [NCT05027126]Phase 136 participants (Actual)Interventional2019-02-28Completed
Effectiveness of Dexketoprofen Trometamol in the Management of Postoperative Endodontic Pain. Controlled Clinical Trial of Multiple Doses [NCT02086097]Phase 490 participants (Actual)Interventional2013-08-31Completed
Parecoxib vs. Dexketoprofen in Combination With Acetaminophen as Additional Analgesia in Patients With Neuraxial Morphine for the Management of Pain After Cesarean Section. A Randomized, Double Blind, Controlled Trial. [NCT04847024]380 participants (Actual)Interventional2019-07-01Completed
Comparison of Postoperative Analgesic Efficacy of Preemptive Ultrasound-guided Transversus Abdominis Plane Block, Ultrasound-guided Local Infiltration and Intravenous Dexketoprofen in Inguinal Hernia Repair [NCT04227912]120 participants (Actual)Interventional2019-02-11Completed
The Efficacy of Intravenous Paracetamol Versus Dexketoprofen for Postoperative Pain Management After Septoplasty: A Prospective Randomized Double Blind Study [NCT02602197]Phase 32 participants (Actual)Interventional2013-08-31Active, not recruiting
Evaluation of the Efficacy of Different Drugs in the Treatment of the Pain in Patients With Temporomandibular Disorder [NCT05529290]Phase 4200 participants (Actual)Interventional2019-07-16Completed
EVALUATION OF ORAL USE OF DEXKETOPROFEN/TRAMADOL IN ACUTE POSTOPERATIVE PAIN IN PATIENTS UNDERGOING TOTAL HIP REPLACEMENT WITH A MINIMALLY INVASIVE ANTERIOR APPROACH (AMIS). [NCT04178109]Phase 2226 participants (Actual)Interventional2019-01-10Completed
Evaluation of Dexketoprofen Given Intravenous or Intrathecal in Postoperative Pain in Patients Undergoing Total Knee Arthroplasty [NCT04161690]Phase 2120 participants (Anticipated)Interventional2019-11-06Recruiting
The Central Nervous Penetration of Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Reaction in Patients Undergoing Hip Arthroplasty [NCT02568735]Phase 424 participants (Actual)Interventional2013-01-31Completed
Erector Spinae Plane Block Versus Intravenous Dexketoprofen-trometamol for Treatment of Reno-ureteral Colic: a Randomized Prospective Study [NCT04209439]Phase 440 participants (Actual)Interventional2019-01-01Completed
Comparison of Analgesic Efficacy of Dexketoprofen and Ibuprofen in Long Bone Fractures: Randomised Controlled Double-blind Study [NCT06060236]Phase 4100 participants (Anticipated)Interventional2023-09-01Recruiting
Intravenous Metoclopramide Versus Dexketoprofen Trometamol Versus Metoclopramide+ Dexketoprofen Trometamol in Acute Migraine Attack in the Emergency Department: a Randomized Double-blind Controlled Trial [NCT04252521]150 participants (Actual)Interventional2019-07-03Completed
Comparison of iv Paracetamol, iv Dexketoprofen and Topical Lidocaine in Scorpion Sting: a Placebo Randomized Controlled Trial [NCT05125796]106 participants (Actual)Interventional2020-09-01Completed
Comparison of The Effectiveness of Intravenous Paracetamol, Dexketoprofen and Ibuprofen In The Treatment of Non-Traumatic Acute Low Back Pain In The Emergency Department [NCT04609254]Phase 4210 participants (Actual)Interventional2018-12-15Completed
Comparison Of The Effectiveness Of Submucosal Corticosteroid Injection And Elastic Therapeutic Bandage Applications On Pain, Swelling And Trismus After Surgical Removal Of Mandibular Third Molar Teeth [NCT04200885]Phase 452 participants (Actual)Interventional2019-05-02Completed
Comparison of Efficacy and Safety of the Postoperative Analgesia Methods for Supratentorial Craniotomy by Integrated Pulmonary Index (IPI) [NCT02929147]Phase 490 participants (Anticipated)Interventional2016-11-30Not yet recruiting
[NCT01947205]111 participants (Actual)Interventional2012-11-30Completed
Intercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block, Ultrasound Guided Blocks for no Reconstructive Breast Surgery. Randomized Trial [NCT02018601]Phase 4120 participants (Anticipated)Interventional2013-09-30Recruiting
Effects of COX 1-2 Inhibitors on Prevention of Rocuronium Injection Pain: Controlled, Randomised, Double Blind Study [NCT04582032]68 participants (Actual)Interventional2020-11-01Completed
Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies [NCT04313374]Phase 490 participants (Actual)Interventional2016-08-01Completed
Efficacy and Safety of the Combination Dexketoprofen / Vitamin B vs Dexketoprofen in the Treatment of Pain in Patients With Post-traumatic Cervical Sprain Grade I-II of the Quebec Scale. [NCT05001555]Phase 3174 participants (Actual)Interventional2021-11-23Completed
Pamukkale University Medical School,Dept. of Emergency Medicine [NCT01422291]Phase 4120 participants (Actual)Interventional2011-01-31Completed
Evaluation of Multimodal Analgesia Methods in Patients Who Underwent IPACK Block in Total Knee Arthroplasty [NCT04213287]70 participants (Anticipated)Interventional2019-12-23Recruiting
Randomized Clinical Trial to Evaluate the Utility of CYP2D6 Genotyping to Improve the Efficacy and Safety of Tramadol in the Treatment of Acute Postoperative Pain. [NCT05657704]Phase 4300 participants (Anticipated)Interventional2022-10-05Recruiting
Does Preventive Single Dose of Intravenous Dexketoprofen Reduce Pain and Swelling After Orthognathic Surgery? A Prospective, Randomized, Double Blind Clinical Trial [NCT05303688]30 participants (Actual)Interventional2018-03-01Completed
Study of Comparing Dexketoprofen to Placebo in Migraine Attack [NCT02159547]Phase 4224 participants (Actual)Interventional2014-05-31Completed
Double-blind, Randomised, Placebo and Active Controlled, Parallel Group Study to Evaluate the Analgesic Effect of a Single Oral Administration of Four Different Combination Doses of DKP.TRIS With TRAM.HCL in Comparison With the Single Agents, on Moderate [NCT01307020]Phase 2745 participants (Actual)Interventional2011-02-28Completed
The Effect on Knee Joint Loads of Instruction in Analgesic Use Compared With NEUROMUSCULAR Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT [NCT01638962]93 participants (Actual)Interventional2012-08-31Completed
The Comparison of the Effectiveness of Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack in Emergency Service [NCT01730326]Phase 4200 participants (Actual)Interventional2012-03-31Completed
Oral Tramadol Versus Oral Dexketoprofen for Reducing Pain During Office Hysteroscopy in Post Menopausal Women [NCT03585036]Phase 3210 participants (Anticipated)Interventional2018-07-31Not yet recruiting
Intraoperative Use of Dexketoprofen Trometamol, Tramadol Hcl, Pethidine Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication [NCT01558622]Phase 472 participants (Anticipated)Interventional2012-03-31Active, not recruiting
Randomized, Double-blind, Placebo-controlled, Parallel Arm Group Study Evaluating Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride on Moderate to Severe Acute Pain in Patients With Acute Low Back Pain [NCT05170841]Phase 4544 participants (Actual)Interventional2020-09-17Completed
Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration [NCT02380001]Phase 460 participants (Actual)Interventional2015-01-31Completed
Impact of Preemptive Intravenous Ibuprofen on Postoperative Edema and Trismus in the Third Molar Teeth [NCT03170713]60 participants (Anticipated)Interventional2017-05-15Active, not recruiting
Post-operative Morphine Consumption in Obese Patients Undergoing Laparoscopic Bariatric Surgery Following Ketamina and Lidocaine Perfusion [NCT05591105]60 participants (Actual)Observational2022-01-15Completed
A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain Following Abdomina [NCT01904149]Phase 3606 participants (Actual)Interventional2013-05-31Completed
Comparison of the Effect of Intravenous Paracetamol, Dexketoprofen and Ibuprofen on Visual Analogue Scale (VAS) in the Treatment of Acute Migraine Attack Headache in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial [NCT04372264]Phase 4210 participants (Actual)Interventional2018-10-15Active, not recruiting
A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain After Elective Uni [NCT01902134]Phase 3641 participants (Actual)Interventional2013-04-30Completed
Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Traumatic Musculoskeletal Pain in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial [NCT03428503]Phase 4200 participants (Actual)Interventional2015-12-31Completed
Determination of the Effects of Change in Anxiety Level on Pain Perception in Patients Who Present to Emergency Department Due to Acute Pain: a Double Blind, Randomized, Controlled Trial [NCT03420911]180 participants (Actual)Interventional2013-06-30Completed
Comparative Study of the Bioavailability of Dexketoprofen Trometamol Following Single Doses of 25mg Enantyum® Oral Solution vs. Keral® Tablets in Healthy Subjects [NCT02209454]Phase 126 participants (Actual)Interventional2014-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01307020 (3) [back to overview]Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.
NCT01307020 (3) [back to overview]Percentage of Patients Using Rescue Medication at 6 Hours
NCT01307020 (3) [back to overview]Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.
NCT01902134 (4) [back to overview]Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)
NCT01902134 (4) [back to overview]Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)
NCT01902134 (4) [back to overview]SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)
NCT01902134 (4) [back to overview]SPID8 (Sum of Pain Intensity Differences Over 8 Hours)
NCT01904149 (4) [back to overview]Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)
NCT01904149 (4) [back to overview]Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)
NCT01904149 (4) [back to overview]SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)
NCT01904149 (4) [back to overview]SPID8 (Sum of Pain Intensity Differences Over 8 Hours)
NCT02159547 (2) [back to overview]Adverse Effects
NCT02159547 (2) [back to overview]Visual Analogue Scale Change
NCT02209454 (5) [back to overview]AUC(0-∞)
NCT02209454 (5) [back to overview]AUC(0-t)
NCT02209454 (5) [back to overview]Cmax
NCT02209454 (5) [back to overview]t1/2
NCT02209454 (5) [back to overview]Tmax
NCT02777970 (6) [back to overview]% of Patients Achieving 50% of Max TOTPAR
NCT02777970 (6) [back to overview]% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose
NCT02777970 (6) [back to overview]% of Patients Requiring RM (Rescue Medication)
NCT02777970 (6) [back to overview]PGE (Patient Global Evaluation)
NCT02777970 (6) [back to overview]Time to Confirmed FPPAR (First Perceptible Pain Relief)
NCT02777970 (6) [back to overview]TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)

Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 6 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 6 hour (maxTOTPAR6h= 24). Unit of measure is % (NCT01307020)
Timeframe: 6 hours

Interventionpercentage of patients (Number)
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg36.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg59.7
DKP-TRIS 25mg - TRAM.HCl 37.5mg55.6
DKP-TRIS 25mg - TRAM.HCl 75mg72.1
DKP-TRIS 12.5mg26.7
DKP-TRIS 25mg55.0
TRAM.HCl 37.5mg10.2
TRAM.HCl 75mg25.4
Ibuprofen 400mg45.0
Placebo9.7

[back to top]

Percentage of Patients Using Rescue Medication at 6 Hours

Percentage of patients using rescue medication at 6 hours post-dosing. (NCT01307020)
Timeframe: Baseline to 6 hours

Interventionpercentage of patients (Number)
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg66.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg46.8
DKP-TRIS 25mg - TRAM.HCl 37.5mg39.7
DKP-TRIS 25mg - TRAM.HCl 75mg37.7
DKP-TRIS 12.5mg65.0
DKP-TRIS 25mg53.3
TRAM.HCl 37.5mg69.5
TRAM.HCl 75mg64.4
Ibuprofen 400mg48.3
Placebo72.6

[back to top]

Percentage of Patients Achieving at Least 50 % of the Theoretical Maximum Total Pain Relief Score at 4, 8 and 12 Hours Post-dosing.

Pain relief is measured by a verbal rating scale (ranging from 0=none to 4=complete). Theoretical maximum TOTPAR at 6 hours is calculated by summing up the maximum score of analgesia which the patient can attribute at defined time points along 4, 8 and 12 hours(maxTOTPAR4h= 16, maxTOTPAR8h= 32 and maxTOTPAR12h= 48, respectively) Unit of measure is % (NCT01307020)
Timeframe: 4, 8 and 12 hours

,,,,,,,,,
Interventionpercentage of patient (Number)
at 4 hours post-doseat 8 hours post-doseat 12 hours post-dose
DKP-TRIS 12.5mg40.016.710.0
DKP-TRIS 12.5mg - TRAM.HCl 37.5mg63.321.711.7
DKP-TRIS 12.5mg - TRAM.HCl 75mg72.648.435.5
DKP-TRIS 25mg65.031.713.3
DKP-TRIS 25mg - TRAM.HCl 37.5mg65.144.428.6
DKP-TRIS 25mg - TRAM.HCl 75mg78.754.137.7
Ibuprofen 400mg56.733.325.0
Placebo6.56.56.5
TRAM.HCl 37.5mg11.96.85.1
TRAM.HCl 75mg23.720.315.3

[back to top]

Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

"Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores.~The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo." (NCT01902134)
Timeframe: over 8 hours after the first dose

Interventionpercentage of participants (Number)
DKP/TRAM57.9
DEXKETOPROFEN56.5
TRAMADOL51.9
PLACEBO37.9

[back to top]

Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

"Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS < 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable),over 48 hours of the multiple-dose phase.~The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL." (NCT01902134)
Timeframe: over 48 hours of the multiple-dose phase

Interventionpercentage of participants (Number)
DKP/TRAM90.1
DEXKETOPROFEN76.6
TRAMADOL82.2

[back to top]

SPID48 (Sum of Pain Intensity Differences Over First 48 Hours of the Multiple-dose Phase)

"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.~PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.~The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL." (NCT01902134)
Timeframe: over 48 hours of the multiple-dose phase

Interventionunits on a scale (Mean)
DKP/TRAM1943.7
DEXKETOPROFEN1677.5
TRAMADOL1765.6

[back to top]

SPID8 (Sum of Pain Intensity Differences Over 8 Hours)

"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.~The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo." (NCT01902134)
Timeframe: over 8 hours after the first dose

Interventionunits on a scale (Mean)
DKP/TRAM246.9
DEXKETOPROFEN208.8
TRAMADOL204.6
PLACEBO151.1

[back to top]

Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

"Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores.~The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo." (NCT01904149)
Timeframe: over 8 hours after first dose

Interventionpercentage of participants (Number)
DKP/TRAM65.8
DEXKETOPROFEN47.7
TRAMADOL44.0
PLACEBO30.7

[back to top]

Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

"Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS < 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable), over 48 hours of the multiple-dose phase.~The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL." (NCT01904149)
Timeframe: over 48 hours of the multiple-dose phase

Interventionpercentage of participants (Number)
DKP/TRAM94.1
DEXKETOPROFEN82.7
TRAMADOL88.6

[back to top]

SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)

"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.~PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.~The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL." (NCT01904149)
Timeframe: over 48 hours of the multiple-dose phase

Interventionunits on a scale (Mean)
DKP/TRAM2273.0
DEXKETOPROFEN1965.2
TRAMADOL2035.0

[back to top]

SPID8 (Sum of Pain Intensity Differences Over 8 Hours)

"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.~The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo." (NCT01904149)
Timeframe: over 8 hours after the first dose

Interventionunits on a scale (Mean)
DKP/TRAM241.8
DEXKETOPROFEN184.5
TRAMADOL157.3
PLACEBO117.0

[back to top]

Adverse Effects

The adverse effects is being recorded to the study form after the study drugs are administered at the 45th minutes. (NCT02159547)
Timeframe: 45th minutes

Interventionparticipants (Number)
Dexketoprofen0
Normal Slaline0

[back to top]

Visual Analogue Scale Change

Change from baseline in Visual Analogue Scale, 100 mm, at 45th minutes. Visual Analogue Scale is measurement tool scoring tool between 0 (no pain) and 100 mm (worst pain). Minimum clinically significant change in pain score is 13 or 16 mm. (NCT02159547)
Timeframe: 45 minutes

Interventionunits on a scale (Median)
Dexketoprofen55
Normal Slaline30

[back to top]

AUC(0-∞)

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively. (NCT02209454)
Timeframe: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Interventionh*ng/mL (Geometric Mean)
Enantyum® Oral Solution3473.00
Keral® Tablet3485.60

[back to top]

AUC(0-t)

The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 125.00% for AUC(0-t). (NCT02209454)
Timeframe: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Interventionh*ng/mL (Geometric Mean)
Enantyum® Oral Solution3362.20
Keral® Tablet3372.00

[back to top]

Cmax

The absence of any difference in the rate and extent of absorption will be demonstrated if the 90% CI for the geometric mean ratio between Test and Reference formulations is within the range 80.00% - 133.00% for Cmax. (NCT02209454)
Timeframe: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Interventionng/mL (Geometric Mean)
Enantyum® Oral Solution3290.70
Keral® Tablet2785.90

[back to top]

t1/2

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax) and t1/2 will be summarized descriptively. (NCT02209454)
Timeframe: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Interventionh (Geometric Mean)
Enantyum® Oral Solution1.34
Keral® Tablet1.30

[back to top]

Tmax

AUC(0-∞) will be analysed similarly to AUC(0-t) and Cmax. Time to achieve maximum plasma concentration (tmax). (NCT02209454)
Timeframe: Up to 24h post-dose (pre-dose, T+5', T+10', T+15', T+20', T+30', T+40', T+50', T+1h, T+1.25h, T+1.5h, T+2h, T+3h, T+3.5h, T+4h, T+5h, T+6h, T+8h, T+12h and T+24h post-dose).

Interventionh (Median)
Enantyum® Oral Solution0.25
Keral® Tablet0.50

[back to top]

% of Patients Achieving 50% of Max TOTPAR

"Percentage of patients who achieved at least 50% of the maximum TOTPAR at 8 hours. In the present trial the achievable TOTPAR over 8 hours ranges between 0 and 32." (NCT02777970)
Timeframe: 8 hours post-dose

Interventionpercentage of patients (Number)
Tramadol/Dexketoprofen47.7
Tramadol/Paracetamol35.5
Placebo5.3

[back to top]

% of Patients Achieving at Least 30% of PI (Pain Intensity) Reduction Over 8 Hours Post-dose

Percentage of patients who achieve at least 30% of PI Reduction versus baseline Over 8 Hours Post-dose. Percentage change of PI is calculated using the baseline value minus the PI assessed at 8 hours post-dose divided for the baseline value, then multiplied for 100. (NCT02777970)
Timeframe: 8 hours post-dose

Interventionpercentage of patients (Number)
Tramadol/Dexketoprofen40.0
Tramadol/Paracetamol35.5
Placebo9.9

[back to top]

% of Patients Requiring RM (Rescue Medication)

Percentage of patients who required RM within the first over 8 hours post-dose. (NCT02777970)
Timeframe: 8 hours post-dose

Interventionpercentage of patients (Number)
Tramadol/Dexketoprofen51.2
Tramadol/Paracetamol55.0
Placebo88.5

[back to top]

PGE (Patient Global Evaluation)

PGE of the study medication (measured according to a five-point VRS from 1 = poor to 5 = excellent) at 8 hours post-dose or whenever the patient uses Rescue Medication (RM). (NCT02777970)
Timeframe: 8 hours postdose

Interventionunits on a scale (Mean)
Tramadol/Dexketoprofen3.6
Tramadol/Paracetamol2.8
Placebo1.5

[back to top]

Time to Confirmed FPPAR (First Perceptible Pain Relief)

"Time to confirmed FPPAR (time to onset of analgesia) - i.e. time to FPPAR if confirmed by experiencing Meaningful Pain Relief (MPAR)~FPPAR and MPAR assessed by using stopwatches:~'first perceptible' PAR (FPPAR), i.e, at the moment they first felt any PAR whatsoever;~'meaningful' PAR (MPAR, ie, when the relief from pain became meaningful to them)" (NCT02777970)
Timeframe: 2 hours post-dose

Interventionminutes (Median)
Tramadol/Dexketoprofen21
Tramadol/Paracetamol24

[back to top]

TOTPAR6 (Total Pain Relief Over 6 Hours Post-dose)

"TOTPAR calculated as the weighted sum of the PAR scores, measured according to a 5-point VRS (Verbal Rating Scale) from 0=no relief to 4=complete relief, over 6 hours post-dose (TOTPAR6).~The TOTPAR6 ranges from a minimum of 0 to a maximum of 24." (NCT02777970)
Timeframe: 6 hours post-dose

Intervention5-point Verbal Rating Scale (Mean)
Tramadol/Dexketoprofen13.0
Tramadol/Paracetamol9.2
Placebo1.9

[back to top]